Genetic Signatures

Genetic Signatures EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 0.30. In the previous year, EV/Revenue (Enterprise Value to Revenue) was -0.28 — a change of -208.83% (higher).

EV/Revenue

0.30

YoY

-208.83%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Genetic Signatures is 2026 0.30 . EV/Revenue (Enterprise Value to Revenue) of Genetic Signatures was 2025 -0.28 . It decreases by -208.83% higher compared to the previous year.

The Genetic Signatures EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2019
2.93 AUD
Jan 1, 2020
-0.38 AUD
Jan 1, 2021
-0.13 AUD
Jan 1, 2022
-0.30 AUD
Jan 1, 2023
0.58 AUD
Jan 1, 2024
-0.91 AUD
Jan 1, 2025
-0.28 AUD
Jan 1, 2026
0.30 AUD
The Genetic Signatures EV/Revenue history
YEAREV/RevenueYoY
0.30-208.83%
-0.28-69.79%
-0.91-258.15%
0.58-290.23%
-0.30+138.20%
-0.13-66.76%
-0.38-113.09%
2.93-14.89%
3.44+8.00%
3.18-55.87%
7.21-63.57%
19.80+139.20%
8.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

EV/Revenue (Enterprise Value to Revenue) of Genetic Signatures is 0.30 in 2026.

EV/Revenue (Enterprise Value to Revenue) of Genetic Signatures changed from -0.28 to 0.30, representing a -208.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genetic Signatures

All Key Metrics — Genetic Signatures